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Abstract
Objective The objective of this study was to assess the
cost effectiveness of commonly used antidepressants as
first-line treatment of major depressive disorder (MDD) in
Belgium.
Methods The model structure was based on a decision
tree developed by the Swedish TLV (Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket) and adapted to the Belgium
healthcare setting, using primary local data on the pat-
terns of treatment and following KCE [Federal Knowl-
edge Center (Federaal Kenniscentrum voor de
Gezondheidszorg)] recommendations. Comparators were
escitalopram, citalopram, fluoxetine, paroxetine, sertra-
line, duloxetine, venlafaxine, and mirtazapine. In the
model, patients not achieving remission or relapsing after
remission on the assessed treatment moved to a second
therapeutic step (titration, switch, add-on, or transfer to a
specialist). In case of failure in the second step or fol-
lowing a suicide attempt, patients were assumed to be
referred to secondary care. The time horizon was 1 year
and the analysis was conducted from the National
Institute for Health and Disability Insurance (NIHDI;
national health insurance) and societal perspectives.
Remission rates were obtained from the TLV network
meta-analysis and risk of relapse, efficacy following
therapeutic change, risk of suicide attempts and related
death, utilities, costs (2012), and resources were derived
from the published literature and expert opinion. The
effect of uncertainty in model parameters was estimated
through scenario analyses and a probabilistic sensitivity
analysis (PSA).
Results In the base-case analysis, escitalopram was
identified as the optimal strategy: it dominated all other
treatments except venlafaxine from the NIHDI perspective,
against which it was cost effective with an incremental
cost-effectiveness ratio of €6,352 per quality-adjusted life-
year (QALY). Escitalopram also dominated all other
treatments from the societal perspective. At a threshold of
€30,000 per QALY and from the NIHDI perspective, the
PSA showed that the probability of escitalopram being
identified as the optimal strategy ranged from 61 % (vs.
venlafaxine) to 100 % (vs. fluoxetine).
Conclusion Escitalopram was associated with the highest
probability of being the optimal treatment from the NIHDI
and societal perspectives. This analysis, based on new
Belgian clinical practice data and following KCE require-
ments, provides additional information that may be used to
guide the choice of treatments in the management of MDD
in Belgium.
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Key Points for Decision Makers
There is currently no published guideline on the
management of major depressive disorder (MDD) in
Belgium.
The most recent assessment of the cost effectiveness
of antidepressants in Belgium was published in 2005.
Our study updates the cost-effectiveness assessment
of first-line pharmaceutical treatment of MDD in
Belgium, reflecting current clinical practice and
considering all relevant comparators.
Our model was based on the TLV (Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket) model developed with the
aim to reassess antidepressants in Sweden following
the implementation of new reimbursement rules.
In the base-case analysis, escitalopram dominated all
the comparators except venlafaxine from the national
health insurance (National Institute for Health and
Disability Insurance; NIHDI) perspective, and all the
comparators from the societal perspective.
Escitalopram was associated with the highest
probability of being the optimal treatment from the
NIHDI and societal perspectives.
1 Introduction
Major depressive disorder (MDD), or unipolar disorder,
affects approximately 121 million people worldwide and
30.3 million in Europe, and places a considerable burden
on society [2, 3]. MDD is a mental disorder generally
characterized by the presence of one pole of persistent low
mood (unlike alternating episodes of low and high mood in
bipolar disorder), and a loss of interest and pleasure [4, 5].
In 2011, the median prevalence was estimated at 6.9 % in
Europe and depression was the most important contributor
to burden of disease among mental and other disorders of
the brain [7.2 % of the overall European disability-adjusted
life-years (DALYs), and 40.5 % of the DALYs caused by
mental and substance use disorders worldwide] [3, 6]. The
number of deaths due to suicides in people suffering from
depression is estimated at 850,000 per year worldwide [2].
In Belgium, the lifetime prevalence of MDD was esti-
mated at 13.6 % in 2004 [7] and the global costs of anti-
depressants represented 7.2 % of the pharmaceutical
expenses prescribed in ambulatory care [8]. In 2008, the
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering/
Institut Nationale d’Assurance Maladie et Invalidite´,
referred to as the National Institute for Health and Dis-
ability Insurance (NIHDI), reimbursed more than 20 anti-
depressants in Belgium, classified according to four main
categories: tricyclic antidepressants, selective serotonin
reuptake inhibitors (SSRIs), monoamine oxidase inhibitors,
and others including the serotonin–norepinephrine reuptake
inhibitors (SNRIs) [9]. SSRI antidepressants were intro-
duced in the early 1990s and they accounted for 60 % of
the prescriptions of antidepressants in Belgium in 2009 [10,
11]. Notwithstanding the context, there is no current clear
published recommendation for the management of
depression in Belgium, nor is the extent to which the dif-
ferences in clinical benefits between the different drugs
translate into economic benefits clear. The most recently
published cost-effectiveness analysis is from 2005 [12] and
concluded that escitalopram was cost effective compared to
citalopram (SSRI) and venlafaxine (SRNI) in the treatment
of MDD in Belgium. More recent international studies
reported that SSRIs were a cost-effective option, specifi-
cally escitalopram [1, 13]. Therefore, this analysis aimed to
provide a more up-to-date assessment, but also taking into
account the incremental cost per quality-adjusted life-year
(QALY) and the currently most prescribed antidepressants
(which were based on all relevant antidepressants included
in the scope of the review by the Swedish Dental and
Pharmaceutical Benefits Board (Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket; TLV) [1]).
Based on an adaptation of an existing economic evalu-
ation [1] and new local data on the clinical management
patterns of depression in Belgian care settings [14], we
sought to assess the cost effectiveness of the most relevant
pharmaceutical treatment options in the first-line manage-
ment of MDD in Belgium.
2 Methods
2.1 Overview
The cost-effectiveness analysis was developed based on a
recent model published by the Swedish Dental and Phar-
maceutical Benefits Board (TLV) [1]. In addition to having
been developed by a governmental health authority, the
model was populated using its own network meta-analyses
results, reinforcing the robustness of the analysis. Our
adaptation of the TLV model and the corresponding eco-
nomic analyses were performed according to the Belgian
guidelines for health economic studies, established by the
Federal Knowledge Center (KCE; Federaal Kenniscentrum
voor de Gezondheidszorg) (see the Electronic Supple-
mentary Material, Technical Appendix—Table I [15]), and
adapted to Belgian treatment patterns, considering only two
therapeutic steps. In order to reflect local practices, the
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treatment pathways for a typical patient with MDD in
Belgium were derived from a local survey conducted in
2011 by the Department of Psychiatry of the Universitair
Psychiatrisch Centrum (UPC; KU Leuven, Belgium) [14].
The most commonly used antidepressants were identified
by clinical experts and included citalopram 20 mg/day
(generic), fluoxetine 20 mg/day (generic), paroxetine
20 mg/day (generic), sertraline 50 mg/day (generic), dul-
oxetine 60 mg/day, venlafaxine 75 mg/day (generic),
mirtazapine 30 mg/day (generic), and escitalopram 10 mg/
day. For each of these treatments, QALYs and costs (from
the NIHDI and societal perspectives) for an average patient
were assessed after/over 12 months.
2.2 Decision Tree Model
The decision tree describing possible outcomes and medi-
cal management decisions within a period of 1 year is
shown in Fig. 1. Pharmacoeconomic analyses were con-
ducted using the software Microsoft Excel, version 2007
(Microsoft Corporation, Redmont, WA, USA). Following
initial treatment, patients were assumed to achieve remis-
sion or to change therapy. After achieving remission,
patients could either relapse or remain on maintenance
therapy until the end of the 12 months. Patients who
relapsed or did not achieve remission, either due to lack of
efficacy or lack of tolerability, moved to a second thera-
peutic step, which include one of the four following
strategies if treatment was not effective: (1) increase the
dose of the current therapy (titration); (2) receive another
antidepressant from the same class or from another class
(switch within the class or to another class); (3) add another
therapy to increase the efficacy of the initiation drug,
including combination with bupropion, combination with
psychotherapy, or augmentation with quetiapine (add-on);
or (4) switch to psychotherapy. Following expert opinion
and the TLV approach, it was assumed that patients who
failed to achieve remission or relapsed on the initiated
treatment faced the same risk of suicide attempt regardless
of the type of therapy on which they failed to achieve
remission or relapsed after achieving remission.
Patients who failed to achieve remission following the
second therapeutic step and patients who survived a suicide
attempt were assumed to be transferred to specialist care.
2.3 Model Parameters
2.3.1 Clinical Inputs
Rates of remission on the initiated treatments were derived
from the meta-analysis conducted by the TLV (see Wes-
sling and Ramsberg, Appendix 11 [1] for details), which
considered studies defining remission as a score of 7 or
lower on the 17-item Hamilton Depression Rating Scale
(HAMD) or a score of 12 or lower on the 10-item Mont-
gomery-A˚sberg Depression Rating Scale (MADRS). Data
related to the risk of relapse, efficacy following therapeutic
change, and risk of suicide attempts and related death were
derived from the published literature and expert opinion.
The rate of remission in patients on escitalopram was
estimated at 47.56 %. The range for the seven comparators
was 40.21 % (fluoxetine) to 45.68 % (venlafaxine)
(Table 1). The proportion of patients experiencing relapse
was assumed to be similar across treatments and was set to
Fig. 1 Model structure. Primary care model for major depressive
disorder using a time horizon of 12 months, derived from the Swedish
Tandva˚rds- och la¨kemedelsfo¨rma˚nsverket (TLV) model and adjusted
to the Belgian care settings. Two steps of therapy were considered in
the model. Patients who attempted suicide or failed in the second step
were assumed to be transferred to specialist care. Specialist care
included ambulatory care and hospitalization. MDD major depressive
disorder
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14.2 %, based on a longitudinal study published by Limosin
et al. [16]. Patients who relapsed were assumed to do so
within 4 months of having achieved remission. As no local
data regarding the incidence of fatal suicide and non-fatal
suicide were identified, the publication from Khan et al. [17],
who evaluated suicide based on data from US FDA-reviewed
studies involving 23,201 depressive patients, was used. The
authors reported a rate of suicide of 6.3 per 100 patient-years.
This rate was applied to patients who relapsed or failed to
achieve remission. Based on the same study, 10 % of suicide
attempts were assumed to lead to death.
Remission rates in the second step were mainly obtained
from the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) [18] study and the published litera-
ture. The STAR*D study was implemented by the National
Institute of Mental Health in the USA and aimed to compare
the short- and longer-term treatment outcomes of 3,671
outpatient adults with non-psychotic depression disorder in
41 clinical sites, followed for 1 year. Thus, in case of add-on,
the first-step antidepressant (which was citalopram in
STAR*D) was assumed to be combined with bupropion
150 mg/day and associated with a remission rate of 39 %. A
similar remission rate of 41.9 % was assumed in cases of
transfer to psychotherapy or to specialist care. The remission
rate after augmentation with quetiapine 300 mg/day was
obtained from a pooled analysis of two clinical trials
assessing the efficacy of adjunctive quetiapine in MDD
patients [19], as quetiapine was not used in the STAR*D
study. Efficacy after titration was derived from a study by
Francois et al. [20], who developed a pharmacoeconomic
Table 1 Clinical data and
sources
NA not applicable, SNRI
serotonin–norepinephrine
reuptake inhibitor, SSRI
selective serotonin reuptake
inhibitor, TLV Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket
a SNRI: including mirtazapine
Clinical data Data (%) References
Remission rate in first therapeutic step
SNRIsa
Duloxetine 44.99 Wessling and Ramsberg (TLV) [1]
Venlafaxine 45.68 Wessling and Ramsberg (TLV) [1]
Mirtazapine 45.08 Wessling and Ramsberg (TLV) [1]
SSRIs
Citalopram 40.50 Wessling and Ramsberg (TLV) [1]
Escitalopram 47.56 Wessling and Ramsberg (TLV) [1]
Fluoxetine 40.21 Wessling and Ramsberg (TLV) [1]
Paroxetine 42.70 Wessling and Ramsberg (TLV) [1]
Sertraline 43.02 Wessling and Ramsberg (TLV) [1]
Remission rate in second therapeutic step
Switch to SNRI (venlafaxine 75 mg/day) 25.00 Rush et al. (STAR*D) [18]
Switch to SSRI (sertraline 50 mg/day) 26.60 Rush et al. (STAR*D) [18]
Switch to psychotherapy 41.90 Rush et al. (STAR*D) [18]
Combination with bupropion 150 mg/day 39.00 Rush et al. (STAR*D) [18]
Combination with psychotherapy 29.40 Rush et al. (STAR*D) [18]
Augmentation with quetiapine 300 mg/day 53.10 Bauer et al. [19]
Titration
SNRIsa
Duloxetine NA
Venlafaxine 37.40 Francois et al. [20]
Mirtazapine 36.91 Francois et al. [20]
SSRIs
Citalopram 23.80 Francois et al. [20]
Escitalopram 36.20 Francois et al. [20]
Fluoxetine 23.80 Francois et al. [20]
Paroxetine 32.50 Francois et al. [20]
Sertraline 32.74 Francois et al. [20]
Risk of relapse
Similar across treatment 14.20 Limosin et al. [16]
Risk of suicide
Attempted suicide 6.30 Kahn et al. [17]
Death after suicide attempt 10.00 Kahn et al. [17]
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model to estimate the cost effectiveness of venlafaxine,
citalopram, escitalopram, and fluoxetine.
2.3.2 Medical Management
Given the absence of therapeutic guidelines and published
data related to the treatment of MDD patients in Belgium,
the results of a Belgian survey were used to simulate the
evolution of patients through the decision tree (Table 2)
[14]. In this questionnaire, physicians were first asked
which treatment class (SNRIs or SSRIs) they more often
used as an initial therapeutic step; they were then asked to
consider subsequent treatment steps according to the rea-
son of treatment change (lack of efficacy or tolerability
issues). The choice of therapeutic changes (switch, titra-
tion, add-on, or transfer to physiotherapist) and time to
events (from initiation to second step, and from second step
to third step) were also collected. Data from 97 question-
naires completed by general practitioners (GPs) were used
to inform the model. Mirtazapine, which is classed as a
tetracyclic antidepressant, was pooled with the SNRIs.
The distribution by reason for therapeutic change in
patients failing to achieve remission, the selection of the
subsequent step, the time to achieve remission, and the
treatment durations after remission for each step were
derived from the mean value of the corresponding item
collected from the 97 questionnaires (see Table 3). The
physicians were asked to provide this information by class
of initial antidepressant: SSRI (including citalopram
20 mg/day, escitalopram 10 mg/day, fluoxetine 20 mg/day,
paroxetine 20 mg/day, and sertraline 50 mg/day) or SNRI
(including duloxetine 60 mg/day, and venlafaxine 75 mg/
day or mirtazapine 30 mg/day).
Following treatment initiation with an SNRI or mirt-
azapine, physicians who decided to make a therapeutic
change did so because of a lack of efficacy in 59 % of cases
and because of tolerability issues in 41 %. For SSRIs, the
main reason for therapeutic change was lack of efficacy (in
73 % of cases vs. 27 % for tolerability issues).
Based on the local survey and clinical expert opinion (a
Belgian professor in psychiatry [21]), we assumed that
therapy change or remission both occurred at the end of a
1.5-month assessment period after the initiation of therapy
(i.e., from the survey, physicians decided on average to
change therapy 6.5 weeks after initiating treatment).
Patients achieving remission were assumed to remain on
maintenance treatment for 6.1 months (26.5 weeks) and
8.2 months (35.5 weeks) in the first and second therapeutic
steps, respectively. When not achieving remission on the
second treatment step, patients were assumed to stay in
non-remission until the end of the 12 months. Finally,
based on Limosin et al. [16], it was assumed that patients
relapsing did so 4 months after remission.
2.3.3 Effectiveness
Utility estimates were derived from Sobocki et al. [22]. In
this naturalistic longitudinal observational study conducted
in Sweden, 447 depressed patients completed the EuroQoL-
5D (EQ-5D) health status questionnaire at each visit. In the
Table 2 Medical management, based on the results of the local
survey [14]
Medical management SNRIa (%) SSRI (%)
Reasons for change
Lack of efficacy 59.43 73.32
Lack of tolerability 40.57 26.68
Therapeutic changes
Lack of tolerability
Switch to SNRI 21.94 53.28
Switch to SSRI 63.25 32.99
Switch to psychotherapy 14.81 13.73
Lack of efficacy
Switch to SNRI 5.41 19.50
Switch to SSRI 12.87 4.54
Titration 45.58 41.40
Combination with bupropion 11.19 9.33
Combination with psychotherapy 16.23 19.70
Augmentation with quetiapine 5.84 3.44
Switch to psychotherapy 2.89 2.09
NA not applicable, SNRI serotonin–norepinephrine reuptake inhibitor,
SSRI selective serotonin reuptake inhibitor
a SNRI: including mirtazapine
Table 3 Time to event and duration of event (in months)
Clinical events
(in months)
Meana SD Min. Max. 95 %
CI
Median
Time to achieve remission/therapeutic change
In first therapeutic
step [14]
1.5 1.2 0.5 12.0 1.3–1.7 1.4
In second
therapeutic step
[14]
2.0 2.5 0.0 23.9 1.5–2.6 1.4
Time to relapse after remission
In first therapeutic
step [16]
4.0
Duration on treatment after achieving remission
In first therapeutic
step [14]
6.1 2.7 1.4 15.6 5.5–6.6 5.5
In second
therapeutic step
[14]
8.2 4.4 1.4 35.9 7.3–9.0 6.9
Max. maximum, Min. minimum, SD standard deviation
a The values were validated by experts and were in accordance with
the guidelines in depression
Cost-Effectiveness Analysis of Pharmaceutical Treatment Options 483
absence of a Swedish social tariff, the authors used UK tariffs
derived from Dolan et al. to estimate the utility scores [23,
24]. At the end of a 6-month follow-up, patients achieving
remission [improved or very much improved on the Clinical
Global Impression–Severity (CGI-S) scale] obtained an
average EQ-5D index value of 0.81 (95 % CI 0.77–0.83).
Patients not achieving remission reached a utility score of
0.57 (95 % CI 0.52–0.60). In the model, patients relapsing
after remission, attempting suicide, or failing to achieve
remission were assumed to experience the same level of
utility. During the assessment period, the mid-point utility
between remission and no remission was used (0.69).
2.3.4 Costs and Resources Used
The analysis was run according two perspectives: the NI-
HDI perspective and the societal perspective. Cost
estimates were based on data from the Belgisch Centrum
voor Farmacotherapeutische Informatie/Centre Belge
d’Information Pharmacothe´rapeutique (BCFI/CBIP) and
published literature. No discount was applied to costs as the
time horizon of the study is 1 year (Table 4). All costs
were updated when necessary to 2011 prices based on the
Belgian Harmonised Index of Consumer Price for health
(HICP) [25].
In line with the efficacy assumptions, the costs associ-
ated with the therapies that were used to compute the
remission rates in the second step were adjusted for each
corresponding therapeutic change option. The costs of
therapies after switching to SNRIs and to SSRIs were set to
the costs of venlafaxine and sertraline, respectively. The
costs after titration were set to the costs of the corre-
sponding increased daily dosage of each treatment. For
add-on therapies, the average cost of first-step treatments
Table 4 Monthly costs in first
and second therapeutic steps
from the National Institute for
Health and Disability Insurance
and societal perspectives
NA not applicable, NIHDI
National Institute for Health and
Disability Insurance, SNRI
serotonin–norepinephrine
reuptake inhibitor, SSRI
selective serotonin reuptake
inhibitor
a SNRI: including mirtazapine
Therapy costs Daily
dose
(mg)
No. of
daily
intakes
Monthly costs (in €) References
NIHDI Societal
In first step
SNRIa
Duloxetine 60 1 34.45 46.55 NIHDI [29], Onkelinx [30]
Venlafaxine 75 1 8.18 11.11
Mirtazapine 30 1 11.18 15.05
SSRI
Citalopram 20 1 8.03 10.92
Escitalopram 10 1 14.03 19.76
Fluoxetine 20 1 4.70 6.35
Paroxetine 20 1 8.50 11.45
Sertraline 50 1 6.99 9.52
In second step
Switch to SNRI (venlafaxine) 75 1 8.18 11.11 NIHDI [29], Onkelinx [30]
Switch to SSRI (sertraline) 50 1 6.99 9.52
Combination with bupropion 300 1 31.37 40.44
Combination with psychotherapy NA NA 51.50 71.72
Augmentation with quetiapine 150 1 44.90 47.29
Titration
SNRIa
Duloxetine 60 2 68.90 93.10
Venlafaxine 150 1 13.00 17.37
Mirtazapine 45 1 9.71 13.14
SSRI
Citalopram 40 1 17.05 21.43
Escitalopram 20 1 28.06 39.51
Fluoxetine 20 2 9.39 12.70
Paroxetine 30 1 10.53 14.18
Sertraline 100 1 8.49 11.55
Switch to psychotherapy alone NA NA 39.50 55.40 NIHDI [29]
Transfer to specialist care NA NA 246.70 309.60 Demyttenaere et al. [12]
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was included (bupropion 150 mg/day for combination with
antidepressant, quetiapine 300 mg/day for augmentation
with a non-antidepressant). Treatment costs after combi-
nation with psychotherapy were computed as the average
costs of a visit to the psychotherapist and the average costs
of treatment in first line. When patients were switched to
psychotherapy alone, the cost of a visit to the psycho-
therapist was applied. The cost of specialist care after
treatment failure in step 2 (no remission or relapse after
remission) or suicide attempt was based on the total direct
cost of the ‘‘expected costs of secondary care’’ from De-
myttenaere et al. [12], who developed a 6-month decision
tree model adapted from Hemels et al. [26] to assess the
cost effectiveness of escitalopram for first-line treatment of
MDD in Belgium. Costs in patients failing to achieve
remission were €886 and €706 for 3 months, from the
societal and insurance system perspectives, respectively,
and included the costs of antidepressant drug (i.e., €151
and €113 for 3 months), hospitalization (i.e., €365 and
€365 for 3 months) and ambulatory care (i.e., €370 and
€228 for 3 months). The monthly costs were computed and
inflated to 2011 prices using the Belgian HICP.
The cost of a suicide attempt was derived from the same
source [12] and the costs associated with fatal suicide
(€3,072; acute costs plus follow-up for the health sector)
were obtained from the report by De Smedt et al. [27]. The
cost of suicide was assumed to be similar from both per-
spectives (NIHDI and societal).
Based on expert opinion, the cost of a visit to a GP and
to a psychotherapist were derived from the costs associ-
ated to beneficiaries without and with preferential status,
respectively, for the NIHDI and the societal perspective
on 1 December 2011 (Table 5). The numbers of GP and
psychotherapist visits by therapeutic options were based
on Demyttenaere et al. [12] and expert opinion (see
Table 5). Patients were assumed to visit their GP once a
month during the initiation phase on first-step therapy,
and then a further three GP visits until the end of the
12 months for patients on maintenance treatment, on
titration, on add-on, or who had switched therapy.
Patients with psychotherapy alone or on specialist care
were assumed to have only one visit to the GP until the
end of the time horizon. Finally, it was assumed that the
proportion of patients on psychotherapy visit a psycho-
therapist once per month.
The total number of workdays lost per month and health
condition was derived from Demyttenaere et al. [12]. The
indirect costs reflecting the loss of productivity were
associated only to the costs of work absenteeism (i.e.,
limited societal perspective). The average daily cost of
absenteeism per employee (i.e., average daily income
guaranteed by the employer for a period of absenteeism of
30 calendar days) was estimated at €264 according to the
friction costs, and accounted for the proportion of patients
employed [28] (Table 6).
2.3.5 Sensitivity Analyses
As this analysis consisted of multiple comparisons, uni-
variate sensitivity analyses cannot be presented using a
tornado diagram given that the costs and outcomes vary for
each of the assessed strategies. Therefore, it was decided to
conduct limited scenario analyses and further explore the
effect of uncertainty through probabilistic sensitivity ana-
lysis (PSA). Two scenario analyses were conducted on the
costs (costs of specialist care from the NIHDI perspective,
and absenteeism costs from the societal perspective) and
one on the probability of attempted suicide following
failure to achieve remission or relapse.
The distributions selected for the PSA were as follows.
The efficacy in the first therapeutic step for escitalopram
was drawn from a beta distribution, for which parameters
were based on the 95 % confidence interval from the TLV
meta-analysis. In order to reflect the uncertainty around the
relative efficacy between the comparators and escitalop-
ram, the relative risks of remission versus escitalopram
were computed. The corresponding variances were esti-
mated using the delta method [32]. As the uncertainty in
the attempted suicide rate was due more to the
Table 5 Resource utilization. Price from National Institute for
Health and Disability Insurance [31] and number of visit from De-
myttenaere et al. [12]
Resource utilization Cost per unit
(in €)
No. of visits
NIHDI Societal
General practitioner visits 16.98a 22.98b
Treatment initiation in first step 1 per month
Maintenance treatment 3 (in total)
Switch 3 (in total)
Titration 3 (in total)
Add-on 3 (in total)
Switch to psychotherapy alone 1 (in total)
Specialist care 1 (in total)
Psychotherapist visits 39.5c 55.38d
Psychotherapist 1 per month
NIHDI National Institute for Health and Disability Insurance
a NIHDI: reference code 101076 (licensed generalist; beneficiaries
without preferential status)
b NIHDI: reference code 101076 (licensed generalist; fees)
c NIHDI: average of reference code 102690 (licensed specialist in
psychiatric) and reference code 109631 (psychotherapy; beneficiaries
without preferential status)
d NIHDI: average of reference code 102690 (licensed specialist in
psychiatric) and reference code 109631 (psychotherapy; fees)
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generalizability of the rates observed by Khan et al. [17]
than to sample variability, a uniform distribution of ±50 %
of the base-case value was selected. The risk of death in
patients attempting suicide was drawn from a beta distri-
bution using the data from the same study [17]. To reflect
the different options of the second therapeutic step, the
medication changes were drawn from a Dirichlet distribu-
tion [33], the parameters of which were derived from the
local survey.
The details of the parameters of the PSA are available in
the Technical Appendix (Electronic Supplementary Mate-
rials Tables I–IV).
3 Results
3.1 Base Case
One typical patient was run through the model and the
corresponding mean costs and outcomes over the 1-year
time horizon on the different treatments are reported in
Table 7. The total costs per assessed treatment are shown
in Fig. 2.
The number of QALYs varied from 0.685 for fluoxetine
to 0.701 for escitalopram.
From the NIHDI perspective, the main cost driver was
specialist care, which accounted for 70 % (duloxetine) to
79 % (fluoxetine) of the total costs and varied from €824 in
patients on escitalopram to €970 in patients on fluoxetine.
The costs of suicide attempts were relatively stable across
treatments and varied slightly with treatment efficacy: from
€103 for the escitalopram strategy to €114 for the fluoxe-
tine and citalopram strategies. The GP costs were very
similar across treatments (€80 or €81).
Escitalopram dominated all the comparators (less costly
and more effective), except venlafaxine, which was slightly
less costly (€1,113 vs. €1,129), resulting in an incremental
cost-effectiveness ratio (ICER) of escitalopram versus
venlafaxine of €6,352 per QALY (Table 7). The efficiency
frontier on the cost-effectiveness plane in Fig. 3 allows
comparison of multiple treatment options [34]. Strategies
are first sorted by descending costs to exclude dominated
strategies and strategies subject to extended dominance
(i.e., dominated by a linear combination of two existing
strategies) before calculating the ICERs between two
consecutive strategies (i.e., in our model, only the ICER
between the escitalopram and venlafaxine strategies was
computed as all the other strategies were dominated by
escitalopram). The optimal strategy is identified as the
strategy associated with the highest ICER below the
maximum willingness to pay (WTP) for an extra QALY. In
this analysis, assuming the maximum WTP exceeds
€6,500, the optimal strategy is escitalopram.
From the societal perspective, productivity loss
explained 90 % of the total costs and was driven by the
probability of remission. As a result, escitalopram was
associated with the lowest cost due to productivity loss
(€11,831). The cost of productivity loss for other treat-
ments varied from €12,118 (venlafaxine) to €13,330 (flu-
oxetine). Escitalopram dominated all comparators from the
societal perspective.
Table 6 Number of absenteeism days per month from Demyttenaere
et al. [12]
Type of medical management Number of absenteeism
days per month
Treatment initiation step 1 1.3
Maintenance treatment 1.3
Therapeutic changes
Switch 2.7
Titration 2
Add-on 2
Switch to psychotherapy 2.7
Specialist care 10
Table 7 Results of the base-case for escitalopram and the seven comparators; total costs from the National Institute for Health and Disability
Insurance and societal perspective and quality-adjusted life-years
NIHDI Total costs (€) QALYs ICER Societal Total costs (€) QALYs ICER
Venlafaxine 1,113 0.698 – Escitalopram 13,245 0.701 –
Escitalopram 1,129 0.701 €6,352 Venlafaxine 13,503 0.698 Dominated
Mirtazapine 1,134 0.697 Dominated Mirtazapine 13,632 0.697 Dominated
Sertraline 1,166 0.693 Dominated Sertraline 14,074 0.693 Dominated
Paroxetine 1,179 0.692 Dominated Duloxetine 14,088 0.695 Dominated
Fluoxetine 1,233 0.685 Dominated Paroxetine 14,147 0.692 Dominated
Citalopram 1,247 0.686 Dominated Citalopram 14,836 0.686 Dominated
Duloxetine 1,257 0.695 Dominated Fluoxetine 14,863 0.685 Dominated
ICER incremental cost-effectiveness ratio, NIHDI National Institute for Health and Disability Insurance, QALYs quality-adjusted life-years
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3.2 Sensitivity Analyses
From the NIHDI perspective, the total costs were sensitive
to the costs of specialist care (i.e., an increase of 50 % of
the specialist care costs led to an increase ranging from 35
to 40 % of the total costs). When increasing the specialist
costs by 100 %, escitalopram dominated all the other
strategies. When increasing the costs of absenteeism by
50 %, total societal costs rose by approximately 45 %, and
escitalopram kept dominating all of the other treatments.
When raising the risk of attempted suicide from 6.3 to
10 %, QALYs decreased by 0.1 %.
When making pairwise comparisons from the NIHDI
perspective, escitalopram was dominant (i.e., more
effective and less costly) in more than 50 % of the 1,000
simulations for each comparator, except versus venlafaxine
(27.0 %) and mirtazapine (43.5 %) (Table 8). Disregarding
venlafaxine or mirtazapine, escitalopram was dominated in
less than 10 % of cases. When compared with SSRIs, es-
citalopram was more effective in[90 % of the simulations
(range 90.5–99.9 %). Compared to SNRIs, escitalopram
was more effective in 69.4–81.4 % of cases.
From the NIHDI perspective, the cost-effectiveness
planes of each assessed strategy overlapped due to the
overlapping of the 95 % confidence intervals related to the
probability of remission (Fig. 4). The scatter of plots for
duloxetine was located above the others due to the higher
price of the drug. The cost-effectiveness plane shows an
Fig. 2 Details of costs from the
(a) National Institute for Health
and Disability Insurance and
(b) societal perspective. GP
general practitioner, SNRI
serotonin–norepinephrine
reuptake inhibitor, SSRI
selective serotonin reuptake
inhibitor
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important relation whereby the increase in QALYs gained
is mirrored by a decrease in incremental total costs. As
treatment efficacy drove the total cost of treatment through
specialist care (i.e., a less efficient treatment will lead to an
increase in specialist care resources important enough that
the medication costs effects will not be big enough to
attenuate), uncertainty in drug efficacy was translated into
a relatively large variation in terms of costs.
From the societal perspective, escitalopram was domi-
nant to all of the comparators in[60 % of the simulations;
i.e., ranging from 62.6 % (venlafaxine) to 99.6 %
(fluoxetine).
At a threshold of €30,000 [35] per QALY and from the
NIHDI perspective, the PSA showed that in comparison to
the each of the comparators, escitalopram had a probability
of between 61 % (vs. venlafaxine) and 100 % (vs. fluoxe-
tine) of being identified as the optimal strategy (Fig. 4).
Moreover, escitalopram had the highest probability of being
the optimal strategy when compared to all treatments from a
threshold of €22,000; e.g., at a threshold of €22,000, escit-
alopram has the highest net benefit [QALY 9 22,000 -
COST] in 30 % of the 1,000 simulations (Fig. 4).
From the societal perspective, the probability that es-
citalopram was identified as the optimal strategy at the
same threshold ranged from 64 % (vs. venlafaxine) to
100 % (vs. fluoxetine).
4 Discussion
Depression is a burdensome disorder, characterized by
relapses or recurrences [36]. The efficacy of treatment
significantly affects the total costs of the disease, mainly
through the cost of specialist care and hospitalization from
a national insurance perspective, and through the high cost
of work absenteeism from a societal perspective. In Bel-
gium, escitalopram was approved by the NIHDI in May
2002 for the treatment of depression [37] and many ther-
apeutic options are currently available to people suffering
from MDD, yet at the time of writing, none are officially
recommended by the Belgian health authorities.
In 2005, Demyttenaere et al. [12] evaluated the cost
effectiveness of escitalopram, citalopram, and venlafaxine
(which became generic in January 2009) in the treatment of
MDD in Belgium. The effectiveness outcome of interest
was successful treatment, defined as patients that achieved
remission within 8 weeks of treatment and did not relapse
over the following 6 months. The study concluded that
escitalopram dominated citalopram and venlafaxine from
the NIHDI and societal perspectives, with higher success
rates and lower costs achieved for escitalopram. Similarly,
our study concluded that escitalopram dominated citalo-
pram from both perspectives and venlafaxine from the
societal perspective. Escitalopram was found to be cost
effective versus venlafaxine from the NIHDI perspective
(€6,352/QALY). However, the total cost difference
between the two treatments was small and varied from
1.5 % in our study to 5.1 % in the study conducted by
Demyttenaere et al. [12]. Our results were consistent with
analyses conducted for other countries [1, 12, 36]. A net-
work meta-analysis conducted by the TLV compared the
efficacy of 18 antidepressants, based on 85 international
studies published between 1975 and 2008 [1]. After
developing a mixed treatments comparison and a health
Fig. 3 Efficiency frontier from the National Institute for Health and Disability Insurance perspective. NIHDI National Institute for Health and
Disability Insurance, QALYs quality-adjust life-years,
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economic model including the new generation of antide-
pressants used in Sweden (citalopram, duloxetine, escita-
lopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine,
reboxetine, sertraline, and venlafaxine), the authors con-
cluded that escitalopram dominated all comparators but
mirtazapine, against which escitalopram was found to be
cost effective. The difference in the results (i.e., mirtaza-
pine not dominated by escitalopram in Sweden, while the
only non-dominated drug vs. escitalopram was venlafaxine
in Belgium) is directly due to the differences between the
drugs’ unit costs between the two countries (i.e., the patent
of venlafaxine expired in 2008 in Sweden).
A more recent network meta-analysis compared the
efficacy of 12 new-generation antidepressants (bupropion,
citalopram, duloxetine, escitalopram, fluoxetine, fluvox-
amine, milnacipran, mirtazapine, paroxetine, reboxetine,
sertraline, and venlafaxine), based on 117 randomized
controlled trials worldwide from 1991 to 2007 [13]. The
authors concluded that mirtazapine, escitalopram, venla-
faxine, and sertraline were significantly more effective than
the other therapies. When taking into account both efficacy
and tolerability, they found a clinical advantage of using
sertraline or escitalopram, both SSRIs.
A recent publication by Nuijten et al. [36] showed that
in The Netherlands, escitalopram was associated with a
gain of 0.0166 QALYs versus citalopram and of 0.0062
versus venlafaxine (compared with 0.0151 and 0.0025,
respectively, in our study). Although not directly compa-
rable due to the country settings, our results relative to
escitalopram were also consistent with this publication; i.e.,
slightly higher QALYs in favor of escitalopram, ranging in
the model from 0.0025 (venlafaxine) to 0.0155
(fluoxetine).
Other cost-effectiveness analyses comparing escitalop-
ram versus venlafaxine found similar results between the
two agents in terms of success rate and cost in the treatment
of MDD. In a British evaluation, the success rate of es-
citalopram and venlafaxine (i.e., MADRS score B12) was
found similar (i.e., 63.5 %) after 6 months, with a small
saving in favor of escitalopram (ranged from £53 to £61)
[38]. In Norway, the success rate after 6 months was
64.2 % for escitalopram and 62.1 % for venlafaxine, with
associated average total costs of 19,661 Norwegian kroner
(NOK) and NOK20,989, respectively [20].
Finally, clinical studies comparing the efficacy between
escitalopram and citalopram have shown significant supe-
riority of escitalopram over citalopram in terms of response
rate (defined as C50 % improvement in MADRS total
score) [39, 40].
To our knowledge, our study is the first to report a cost-
effectiveness assessment of treatments of MDD in Belgium
expressed in terms of incremental cost per QALY. In
addition, this study considered a broad range of compara-
tors (citalopram, venlafaxine, fluoxetine, paroxetine, ser-
traline, duloxetine, venlafaxine, and mirtazapine) to
achieve a better understanding of the optimal treatment
strategy of MDD from a health economic standpoint.
Moreover, the adaptation of a model structure and the use
of a meta-analysis developed by a public and independent
institute (i.e., TLV health technology assessment), guar-
antee a certain level of transparency and technical rigor.
Furthermore, the majority of guidelines suggest that
Table 8 Pairwise comparisons
of escitalopram versus each of
the seven comparators in the
National Institute for Health and
Disability Insurance and
societal perspectives
NIHDI National Institute for
Health and Disability Insurance
Escitalopram
less costly (%)
Escitalopram
more effective (%)
Escitalopram
dominant (%)
Escitalopram
dominated (%)
NIHDI
Citalopram 90.20 99.00 90.20 1.00
Fluoxetine 86.30 99.90 86.30 0.10
Paroxetine 66.70 93.20 66.70 6.80
Sertraline 56.20 90.50 56.20 9.50
Duloxetine 99.20 81.40 81.40 0.80
Venlafaxine 27.00 69.40 27.00 30.60
Mirtazapine 43.50 70.50 43.50 29.50
Societal
Citalopram 98.50 99.10 98.50 0.90
Fluoxetine 99.60 99.90 99.60 0.10
Paroxetine 91.10 92.60 91.10 7.40
Sertraline 89.30 92.60 89.30 7.40
Duloxetine 92.30 84.30 84.30 7.70
Venlafaxine 63.60 67.10 62.60 31.90
Mirtazapine 67.60 70.60 66.20 28.00
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treatment effects from clinical trials are generalizable
across country settings [41].
However, our study is subject to some limitations due to
the assumptions defined when data were not available
(even if these assumptions were validated by expert opin-
ion). By using treatment effects at 12 weeks and assuming
that all patients change medication after 1.5 months should
they fail to achieve remission, we may be overestimating
the utility. However, another source of the model, the
STAR*D [18] study, used an average time to remission of
6 weeks and, moreover, in the management of depression it
is recommended to change medication strategy if no
improvement is observed after 2–6 weeks on treatments
[42]. Furthermore, in practice, a proportion of patients
might remain on the same treatment even if they do not
achieve remission. As an example, according to the local
Fig. 4 Cost-effectiveness acceptability curve from the (a) National Institute for Health and Disability Insurance and (b) societal perspectives.
NIHDI National Institute for Health and Disability Insurance
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survey used to inform this study, approximately 74 % of
patients remain on the first initiated treatment, while
remission rates derived from clinical trials (from the TLV
meta-analysis) did not exceed 50 %. However, as these
practices are difficult to justify, they were not further
investigated [1, 14].
Also in the STAR*D study, the rate of remission fol-
lowing psychotherapy alone was higher than the rate fol-
lowing the combination of citalopram and psychotherapy
(0.4190 vs. 0.2940). However, patients were free to choose
psychotherapy (non-randomized trial), which may account
for the higher rate of remission in the case of psychother-
apy alone. As in real clinical practice, self-selection is
present, so the efficacy of psychotherapy alone was set to
41.9 % in our model.
Since there were no recent data available for the costs of
hospitalization for patients with MDD in Belgium, we
updated the secondary care costs obtained from Demyt-
tenaere et al. [12] based on the HICP for health goods.
Another limitation due to missing data lies in assuming a
similar risk of relapse and utility among treatments and a
similar rate of attempted suicide following treatment fail-
ure (i.e., remission with or without suicide attempt, or
relapse). The rates of suicide were based on trial submitted
to the FDA, which may exclude suicidal patients at base-
line. Thus, the risk of suicide may be slightly underesti-
mated. However, as highlighted above, this risk was
assumed to be similar across treatments. Moreover, due to
a lack of data at the time of analysis, the cost of suicide was
assumed to be similar for both perspectives. A 2013 study
assessing the cost effectiveness of a helpline for suicide
prevention in Belgium estimated the costs related to suicide
at €2,600 (vs. €3,072 in our model) and €60,537, from the
NIHDI and societal perspectives, respectively, which sug-
gests a clear under-estimation of the costs from the societal
perspective [43].
A 1-year time horizon may not be long enough to cap-
ture long-term effects of agents; however, this timeframe
was used because it was long enough to capture a large
proportion of patient relapses, and short enough to be
supported by credible clinical trial data, and so limited the
number of assumptions.
Psychological-based cognitive behavioral therapy
(PBCBT) was not included in the list of comparators for
first line-therapy (only second line) to be consistent with
our primary source of data (i.e., the TLV did not include
PBCBT in its meta-analysis) and thus avoid heterogeneity
by considering several data sources.
The distributions of reasons for medication changes
were based on a sample of 97 GPs, which is limited to
entirely represent clinical practices in Belgian. However, it
was the best available data to reflect local practices and
treatment pathways for a typical patient with MDD in
Belgium, and the variations in GP’s responses were tested
in the sensitivity analyses.
Adverse events were not considered in the analyses, as
their associated costs represent a low proportion of the total
costs of the disease [36]. Moreover, this is not expected to
change the conclusions since escitalopram is generally
well-tolerated and associated with mild and transient
adverse events [44].
Finally, our model faced the same limitations as high-
lighted in the TLV report conclusion, that is to say the use
of data from clinical studies that may not accurately reflect
the effects of antidepressants in real life (e.g., the differ-
ences in terms of treatment effects came from studies with
follow-up periods less than 2 months, which could be
considered too short to capture the impact of the different
treatments on the remission rate).
The multiple comparison analyses via the efficiency
frontier on the cost-effectiveness plan enabled a simulta-
neous assessment of all the treatment options. The same
approach should be used when running scenario or deter-
ministic sensitivity analyses and therefore the full cost-
efficiency frontier may move so that the relevant ICERs
reported compare pairs of strategies other than the base
case. Therefore, the results cannot simply be reported on a
tornado diagram [45]. For this study, we decided to con-
duct a limited scenario analysis to assess the sensitivity of
the results to parameters for which no strong data were
readily available (probability of suicide following failure to
achieve remission or relapse, costs of hospitalization and
costs of absenteeism). Parameter uncertainty was then
analyzed through PSAs (e.g., overlapping of the confidence
intervals between remission rates from the TLV meta-
analyses, variation between clinician answers in the Bel-
gian survey). Finally, in order to not add uncertainty in the
model, no subgroup analysis, which would have required
additional assumptions and data, was conducted.
5 Conclusion
Using multiple comparisons, escitalopram was associated
with the highest probability of being the optimal strategy
from the NIHDI and societal perspectives. This analysis,
based on new clinical data and following the guidelines of
the Belgian KCE, provides additional information that may
be used to guide value-based pricing and reimbursement as
well as the choice of treatments in the management of
MDD in Belgium.
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